DE2527064C3 - Verfahren zur Herstellung eines intravenösen Nativ-Human-Immunglobulin-Präparates mit natürlicher Halbwertszeit und gegenüber dem Ausgangsmaterial unveränderten Antikörperaktivität - Google Patents
Verfahren zur Herstellung eines intravenösen Nativ-Human-Immunglobulin-Präparates mit natürlicher Halbwertszeit und gegenüber dem Ausgangsmaterial unveränderten AntikörperaktivitätInfo
- Publication number
- DE2527064C3 DE2527064C3 DE2527064A DE2527064A DE2527064C3 DE 2527064 C3 DE2527064 C3 DE 2527064C3 DE 2527064 A DE2527064 A DE 2527064A DE 2527064 A DE2527064 A DE 2527064A DE 2527064 C3 DE2527064 C3 DE 2527064C3
- Authority
- DE
- Germany
- Prior art keywords
- life
- intravenous
- human immunoglobulin
- starting material
- production
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims description 10
- 238000001990 intravenous administration Methods 0.000 title claims description 9
- 108060003951 Immunoglobulin Proteins 0.000 title claims description 8
- 102000018358 immunoglobulin Human genes 0.000 title claims description 8
- 230000008569 process Effects 0.000 title claims description 5
- 239000007858 starting material Substances 0.000 title claims description 5
- 230000000694 effects Effects 0.000 title claims description 4
- 238000004519 manufacturing process Methods 0.000 title claims description 3
- 238000002360 preparation method Methods 0.000 title description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims 1
- 230000003171 anti-complementary effect Effects 0.000 description 10
- 108010074605 gamma-Globulins Proteins 0.000 description 8
- 238000005194 fractionation Methods 0.000 description 7
- 206010018910 Haemolysis Diseases 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000008588 hemolysis Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 3
- 229940027941 immunoglobulin g Drugs 0.000 description 3
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 description 2
- 108010089414 Anaphylatoxins Proteins 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000005482 chemotactic factor Substances 0.000 description 2
- 230000004154 complement system Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 229960000380 propiolactone Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 108010032597 Cohn fraction II Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 208000007746 Immunologic Deficiency Syndromes Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
- Y10S530/831—Cohn fractions
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2527064A DE2527064C3 (de) | 1975-06-18 | 1975-06-18 | Verfahren zur Herstellung eines intravenösen Nativ-Human-Immunglobulin-Präparates mit natürlicher Halbwertszeit und gegenüber dem Ausgangsmaterial unveränderten Antikörperaktivität |
| BE167127A BE841950A (fr) | 1975-06-18 | 1976-05-18 | Immunoglobuline humaine, native, administrable par voie intraveineuse et presentant une demi-duree d'activite naturelle |
| US05/687,842 US4082734A (en) | 1975-06-18 | 1976-05-19 | Production of intravenously applicable native human immune globulin having a normal half-life |
| FR7615249A FR2314730A1 (fr) | 1975-06-18 | 1976-05-20 | Immunoglobuline humaine, native, administrable par voie intraveineuse et presentant une demi-duree d'activite naturelle |
| GB21047/76A GB1535977A (en) | 1975-06-18 | 1976-05-21 | Intravenous native human immunoglobulin with natural half-life period |
| AT395576A AT356265B (de) | 1975-06-18 | 1976-05-31 | Verfahren zur herstellung von nicht mehr antikomplementaer wirksamen nativ-human- -immunglobulin zur intravenoesen verabreichung mit natuerlicher halbwertszeit |
| JP51069405A JPS521013A (en) | 1975-06-18 | 1976-06-15 | Natural human immunoglobulin having natural halfflife for vein and production of same |
| CA255,024A CA1053153A (en) | 1975-06-18 | 1976-06-16 | Intravenous native human immune globulin with a natural half life |
| NL7606581A NL7606581A (nl) | 1975-06-18 | 1976-06-17 | Werkwijze ter bereiding van intraveneus natuur- lijk-menselijk-immuunglobuline met een natuur- lijke halfwaardetijd. |
| CH776776A CH628518A5 (de) | 1975-06-18 | 1976-06-17 | Verfahren zur herstellung von intravenoes vertraeglichem nativ-human-immunglobulin mit natuerlicher halbwertszeit. |
| SE7606968A SE7606968L (sv) | 1975-06-18 | 1976-06-17 | Forfarande for framstellning av intravenos nativ-humanimmunglobulin med naturlig halveringstid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2527064A DE2527064C3 (de) | 1975-06-18 | 1975-06-18 | Verfahren zur Herstellung eines intravenösen Nativ-Human-Immunglobulin-Präparates mit natürlicher Halbwertszeit und gegenüber dem Ausgangsmaterial unveränderten Antikörperaktivität |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE2527064A1 DE2527064A1 (de) | 1976-12-23 |
| DE2527064B2 DE2527064B2 (de) | 1979-03-29 |
| DE2527064C3 true DE2527064C3 (de) | 1979-11-15 |
Family
ID=5949318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2527064A Expired DE2527064C3 (de) | 1975-06-18 | 1975-06-18 | Verfahren zur Herstellung eines intravenösen Nativ-Human-Immunglobulin-Präparates mit natürlicher Halbwertszeit und gegenüber dem Ausgangsmaterial unveränderten Antikörperaktivität |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US4082734A (show.php) |
| JP (1) | JPS521013A (show.php) |
| AT (1) | AT356265B (show.php) |
| BE (1) | BE841950A (show.php) |
| CA (1) | CA1053153A (show.php) |
| CH (1) | CH628518A5 (show.php) |
| DE (1) | DE2527064C3 (show.php) |
| FR (1) | FR2314730A1 (show.php) |
| GB (1) | GB1535977A (show.php) |
| NL (1) | NL7606581A (show.php) |
| SE (1) | SE7606968L (show.php) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK139056B (da) * | 1976-04-06 | 1978-12-11 | Nordisk Insulinlab | Fremgangsmåde til udvinding af immunoglobulin, der er egnet til intravenøs indgivelse. |
| US4164495A (en) * | 1976-04-06 | 1979-08-14 | Nordisk Insulinlaboratorium | Method of recovering immunoglobulin using a polyol and an alkanoic acid |
| DE2658334C3 (de) * | 1976-12-23 | 1987-05-07 | Behringwerke Ag, 3550 Marburg | Verfahren zum Herstellen von Immunglobulinpräparationen mit verminderter Komplementaktivität und ein diese enthaltendes Arzneimittel |
| US4374763A (en) * | 1979-09-17 | 1983-02-22 | Morishita Pharmaceutical Co., Ltd. | Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof |
| US4305871A (en) * | 1980-09-02 | 1981-12-15 | Edward Shanbrom | Method of selectively increasing yield and purity of certain cryoprecipitate proteins by heating |
| US4499073A (en) * | 1981-08-24 | 1985-02-12 | Cutter Laboratories, Inc. | Intravenously injectable immune serum globulin |
| ATE19735T1 (de) * | 1982-02-08 | 1986-05-15 | Schweiz Serum & Impfinst | Intravenoes verabreichbares humanes immunglobulin und verfahren zu dessen herstellung. |
| DE3310150A1 (de) * | 1983-03-21 | 1984-09-27 | Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München | Verfahren zur herstellung einer nebenwirkungsfreien igg-immunglobulinloesung fuer die intravenoese applikation |
| DE3344656A1 (de) * | 1983-12-09 | 1985-06-13 | Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München | Verfahren zur herstellung einer serumproteinloesung |
| CH662824A5 (de) * | 1984-02-14 | 1987-10-30 | Graf & Co Ag | Kardiersegment. |
| AU6948787A (en) * | 1986-03-10 | 1987-09-28 | Rubinstein, A.I. | A method for treating gammaglobulin |
| GB8628104D0 (en) * | 1986-11-25 | 1986-12-31 | Connaught Lab | Pasteurization of immunoglobin solutions |
| DE3927111C3 (de) * | 1989-08-17 | 1994-09-01 | Biotest Pharma Gmbh | Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oderIgA-haltiger Immunglobulinpräparate |
| US5256771A (en) * | 1990-04-03 | 1993-10-26 | Miles Inc. | Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation |
| US5219578A (en) * | 1991-02-25 | 1993-06-15 | Innovet, Inc. | Composition and method for immunostimulation in mammals |
| BE1012448A3 (fr) * | 1998-12-07 | 2000-11-07 | S C R L Dept Central De Fracti | Standard utilise dans des tests de diagnostic et/ou de quantification. |
| US20020077276A1 (en) * | 1999-04-27 | 2002-06-20 | Fredeking Terry M. | Compositions and methods for treating hemorrhagic virus infections and other disorders |
| US6893639B2 (en) * | 2001-10-19 | 2005-05-17 | Hemacare Corporation | Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates |
| WO2016033382A1 (en) * | 2014-08-27 | 2016-03-03 | Capnia, Inc. | Methods for immune globulin administration |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1198277A (en) | 1967-09-05 | 1970-07-08 | Ustav Ser A Ockovacich Latek O | Process for the Preparation of Serum Gamma Globulins by Fractionation of Blood Serum, Plasma or Raw Serum Fractions with Quaternary Ammonium Compounds |
| DE1792555C3 (de) | 1968-09-19 | 1980-01-10 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verfahren zur Herstellung einer für die intravenöse Anwendung geeigneten Gammaglobulinlösung |
| US3916026A (en) * | 1968-09-19 | 1975-10-28 | Biotest Serum Institut Gmbh | Method for the preparation of gamma-globulin suitable for intravenous use |
| US3763135A (en) * | 1971-11-08 | 1973-10-02 | Baxter Laboratories Inc | Gamma globulin production from cohn fraction iii using polyethylene glycol |
| CA1007568A (en) * | 1973-12-13 | 1977-03-29 | Michael C. Attwell | Bovine immunoglobulin isolation process |
-
1975
- 1975-06-18 DE DE2527064A patent/DE2527064C3/de not_active Expired
-
1976
- 1976-05-18 BE BE167127A patent/BE841950A/xx not_active IP Right Cessation
- 1976-05-19 US US05/687,842 patent/US4082734A/en not_active Expired - Lifetime
- 1976-05-20 FR FR7615249A patent/FR2314730A1/fr active Granted
- 1976-05-21 GB GB21047/76A patent/GB1535977A/en not_active Expired
- 1976-05-31 AT AT395576A patent/AT356265B/de not_active IP Right Cessation
- 1976-06-15 JP JP51069405A patent/JPS521013A/ja active Granted
- 1976-06-16 CA CA255,024A patent/CA1053153A/en not_active Expired
- 1976-06-17 NL NL7606581A patent/NL7606581A/xx not_active Application Discontinuation
- 1976-06-17 SE SE7606968A patent/SE7606968L/xx not_active Application Discontinuation
- 1976-06-17 CH CH776776A patent/CH628518A5/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA1053153A (en) | 1979-04-24 |
| JPS5516488B2 (show.php) | 1980-05-02 |
| GB1535977A (en) | 1978-12-13 |
| CH628518A5 (de) | 1982-03-15 |
| FR2314730A1 (fr) | 1977-01-14 |
| FR2314730B1 (show.php) | 1978-12-15 |
| NL7606581A (nl) | 1976-12-21 |
| SE7606968L (sv) | 1976-12-19 |
| AT356265B (de) | 1980-04-25 |
| JPS521013A (en) | 1977-01-06 |
| DE2527064B2 (de) | 1979-03-29 |
| BE841950A (fr) | 1976-09-16 |
| ATA395576A (de) | 1979-09-15 |
| DE2527064A1 (de) | 1976-12-23 |
| US4082734A (en) | 1978-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2527064C3 (de) | Verfahren zur Herstellung eines intravenösen Nativ-Human-Immunglobulin-Präparates mit natürlicher Halbwertszeit und gegenüber dem Ausgangsmaterial unveränderten Antikörperaktivität | |
| DE3825429C2 (de) | Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt | |
| DE69232617T2 (de) | Gefriergetrocknete Zubereitung, die einen monoklonalen Antikörper enthält | |
| DE3382716T2 (de) | Verfahren zur Wärmebehandlung von Plasma oder Plasmafraktionen und so erhaltene Zusammensetzungen. | |
| DE69920693T2 (de) | Verfahren zur herstellung von immunoglobulinen zur intravenösen verabreichung und anderen immunoglobulin-produkten | |
| DE3927111C3 (de) | Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oderIgA-haltiger Immunglobulinpräparate | |
| EP0447585B1 (de) | Verfahren zur Herstellung eines intravenös verträglichen Immunglobulin-G-Präparates | |
| DE69821741T2 (de) | Immunoglobulin enthaltende zusammensetzung | |
| EP0122909B1 (de) | Immunglobulin-G-hältige Fraktion | |
| DE3927112C1 (show.php) | ||
| EP0085747B2 (de) | Intravenös verabreichbares humanes Immunglobulin und Verfahren zu dessen Herstellung | |
| DE3781962T2 (de) | Verfahren zur hitzebehandlung von chemisch unmodifiziertem gamma-globulin. | |
| AT390560B (de) | Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern | |
| DE3306060A1 (de) | Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung | |
| EP0123029A1 (de) | Verfahren zur Herstellung einer nebenwirkungsfreien IgG-Immunglobulinlösung für die intravenöse Applikation | |
| EP0234405B1 (de) | Verwendung eines immunglobulinhaltigen Präparates zur Prophylaxe und Therapie von AIDS beim Menschen | |
| DE2639012B2 (de) | Immuntherapeutikum zur Prophylaxe und Therapie von Pseudomonas aeruginosa-Infeklionen | |
| AT402789B (de) | Pharmazeutische präparation auf basis von plasmaproteinen | |
| DE1792555C3 (de) | Verfahren zur Herstellung einer für die intravenöse Anwendung geeigneten Gammaglobulinlösung | |
| DE19831061A1 (de) | Herstellung von Proteinpräparationen mit verringertem Aggregatgehalt | |
| EP0120835A2 (de) | Verfahren zur Inaktivierung von Unverträglichkeitsreaktionen verursachenden Substanzen | |
| EP0249167B1 (de) | Verfahren zur Herstellung einer pasteurisierten Immunglobulinpraeparation | |
| DE19923027A1 (de) | Verfahren zur Inaktivierung von Viren | |
| US3074851A (en) | Fractionation of protein solutions | |
| DE68913212T2 (de) | Ein reines faktor i-protein und verfahren zur herstellung. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) | ||
| 8339 | Ceased/non-payment of the annual fee |